Low-dose rituximab should be used for treating MS in resource-limited settings: Yes-Reference-Cited by-同舟云学术

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes

Published:2022-04-18 Issue:7 Volume:28 Page:1028-1029
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Piehl Fredrik¹^ORCID,Mathew Thomas²^ORCID

Affiliation:

1. Department of Neurology, Karolinska University Hospital and Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

2. Department of Neurology, St. John’s Medical College Hospital, Bengaluru, India

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585221089890

Reference10 articles.

1. Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis

2. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

3. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis

4. Out-of-pocket costs are on the rise for commonly prescribed neurologic medications

5. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Indian multiple sclerosis and allied demyelinating disorders registry and research network (IMSRN): Inception to reality;Multiple Sclerosis and Related Disorders;2024-07

2. COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab;Annals of Neurology;2024-06-25

3. A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis;Multiple Sclerosis and Related Disorders;2022-10